Stockwinners Market Radar for June 28, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

19:31 EDT HP Enterprise expands portfolio with servers based on cloud-native silicon - Hewlett Packard "announced that it is the first major server provider to deliver a new line of cloud-native compute solutions using processors from Ampere. The new HPE solutions provide service providers and enterprises embracing cloud-native development with an agile, extensible, and trusted compute foundation to drive innovation. Available in Q3 2022, the new HPE ProLiant RL300 Gen11 server is the first in a series of HPE ProLiant RL Gen11 servers that deliver next-generation compute performance with higher power efficiency using Ampere Altra(R)and Ampere Altra Max cloud-native processors."

18:43 EDT Novavax presented COVID vaccine data at FDA VRBPAC meeting - Novavax participated in the U.S. Food and Drug Administration Vaccines and Related Biological Products Advisory Committee's meeting which resulted in a 19-2 vote to recommend inclusion of a SARS-CoV-2 Omicron component for COVID-19 booster vaccines in the U.S. beginning this fall. "We are confident that our prototype COVID-19 vaccine generates broad levels of antibodies as a primary series, and that boosting with this prototype vaccine increases the magnitude of the breadth of response," said Gregory M. Glenn, M.D., President of Research and Development, Novavax. "While we believe in the strength of our prototype vaccine data, we are prepared to supply an Omicron-based vaccine this fall in accordance with health authority recommendations." Novavax presented preclinical trial data showing that boosting with either the prototype, Omicron BA.1, or bivalent vaccine generated antibody levels that were consistent with dosing regimens in the Phase 3 clinical trials. While boosting with the prototype covers all strains, providing an Omicron booster enhances immunity to related Omicron sub-variants. Boosting with a bivalent vaccine containing prototype and Omicron BA.1 showed no advantages in any of the responses compared to boosting with BA.1 alone. A clinical trial is ongoing with results anticipated in September and product availability expected in Q4. The Novavax COVID-19 vaccine has not yet been authorized for use in the U.S.

18:36 EDT Harmony Biosciences director sells $5.26M in common stock - In a regulatory filing, Harmony Biosciences disclosed that its director Jack Nielson sold 100.5K shares of common stock on June 24th in a total transaction size of $5.26M.

17:58 EDT ALX Oncology treatment of acute myeloid leukemia granted FDA orphan designation - According to a post on the FDA's website, ALX Oncology's treatment of acute myeloid leukemia was granted orphan designation. Reference Link

17:41 EDT Facebook tests new ways to access Groups and organize them, debuts channels - Maria Smith, VP of Communities, Facebook App blogged in part earlier "Today we're beginning to test new ways to quickly access your favorite Facebook Groups and simplifying how they're organized. We're also introducing channels, which are focused spaces for people to connect in smaller, more casual settings within their communities." Smith continued, "On Facebook, we're testing a new sidebar that helps you easily find your favorite groups more quickly. It will list your groups and the latest activity within them, like new posts or chats you haven't yet seen. You can also pin your favorite groups so they show up first, discover new groups or even create your own. For example, if you want quick access to the latest recipes in your cooking group, you can now pin it to the top, find related groups and be inspired to start your own...Admins can begin to create channels to connect with their groups in smaller, more casual settings where they can have deeper discussions on common interests or organize their communities around topics in different formats...Community chat channels: a place for people to message, collaborate and form deeper relationships around topics in a more real-time way across both Facebook Groups and Messenger....Community audio channels and Community feed channels," Smith posted in part, on the Meta blog.. Reference Link

17:28 EDT Sun Country Airlines to replace Neenah in S&P 600 at open on 7/5 - SchweitzerMauduit International (SWM) is acquiring Neenah (NP) in a transaction expected to be completed on July 1.

17:25 EDT Ormat Technologies to replace CMC Materials in S&P 400 at open on 7/7 - Entegris (ENTG) is acquiring CMC Materials (CCMP) in a transaction expected to be completed on July 6.

17:23 EDT Southwestern Energy to replace CDK Global in S&P 400 at open on 7/6 - Brookfield Business Partners (BBU) is acquiring CDK Global (CDK) in a tender offer expected to be completed on July 5.

17:19 EDT Omnicell to replace Coherent in S&P 400 at open on 7/5 - II-VI (IIVI) is acquiring Coherent (COHR) in a deal expected to be completed on July 1, pending final closing conditions.

16:50 EDT American Acquisition Opportunity Inc (Class A Stock) trading resumes

16:36 EDT Ceragon confirms receipt of letters from Aviat regarding board, potential deal - Ceragon Networks (CRNT) confirmed receipt of two letters from, Aviat Networks (AVNW). The letters include a request to convene an extraordinary general meeting of shareholders calling for a change in the composition of Ceragon's board of directors, whereby Aviat's hand-picked nominees would constitute a majority of the board. The letters also include an indication of interest from Aviat with respect to a potential acquisition of Ceragon.

16:32 EDT Palantir awarded $36M contract by the Army - Palantir Technologies announced that it is one of two companies awarded a prime contract by the Army to build a prototype for the Tactical Intelligence Targeting Access Node, or TITAN, the first Intelligence ground station enabled by Artificial Intelligence and Machine Learning, or AI/ML. The $36M contract award is for the competitive prototyping phase that will span 14 months. The TITAN program brings together a variety of systems, technologies, and vendors to ensure scalability. Palantir's Modular Open System Architecture will be the critical backbone that provides correlation, fusion, and integration of sensor data alongside insights from AI/ML overlaid at the tactical edge.

16:30 EDT Digital Media Solutions names Richard Rodrick CFO - Digital Media Solutions announced that Richard Rodick, CPA, will join the Company and assume the role of CFO on July 1, 2022. To ensure continuity, current CFO Vasundara Srenivas will remain in her role until July 1, at which time she will step down to pursue new career goals. DMS CEO Joe Marinucci said, "DMS has a deep bench of talent driving our success, and I'm extremely pleased to have Richard join DMS as we focus on our next phase of growth. Richard's track record of success as a public company CFO and his outstanding leadership qualities will be an invaluable addition to the DMS leadership team." To help ensure a seamless transition, Srenivas will continue to support DMS in an advisory role until August 19, 2022. Srenivas said, "It has been a pleasure to serve as CFO to DMS. During my tenure, I was fortunate to have the opportunity to collaborate with many talented colleagues and together we experienced significant transformation and growth. I look forward to the Company's continued success."

16:30 EDT 89bio trading resumes

16:23 EDT Disney board unanimously votes to extend CEO Chapek's contract by three years - The Walt Disney Company board "unanimously voted to extend Bob Chapek's contract as Chief Executive Officer for three years." Susan Arnold, Chairman of the Board, said: "In this important time of growth and transformation, the Board is committed to keeping Disney on the successful path it is on today, and Bob's leadership is key to achieving that goal. Bob is the right leader at the right time for The Walt Disney Company, and the Board has full confidence in him and his leadership team."

16:18 EDT Bally's to sell Rhode Island properties to Gaming and Leisure Properties for $1B - Bally's (BALY) announced that it has entered into a binding term sheet with GLP Capital, L.P., the operating partnership of Gaming and Leisure Properties (GLPI), to acquire the real property assets of Bally's two Rhode Island casino properties - Bally's Twin River Lincoln Casino Resort and Bally's Tiverton Casino & Hotel - subject to customary regulatory approvals, with Lincoln also subject to lender consent. Pursuant to the terms of the transaction, Bally's will immediately lease back both properties and continue to own, control, and manage all the gaming operations of the facilities on an uninterrupted basis. Total consideration for the acquisition is $1B. Both properties are expected to be added to the existing Bally's Master Lease between GLPI and Bally's, with incremental rent of $76.3M. The Master Lease has an initial term of 15 years (with 14 years remaining) followed by four five-year renewals at the tenant's option. Normalized rent coverage on the Master Lease - which includes Bally's Dover Casino Resort, Bally's Evansville Casino & Hotel, Bally's Quad Cities Casino & Hotel and Bally's Black Hawk Casinos - is expected to be 2.0x in the first calendar year following the completion of the acquisition of the real property assets of Bally's Rhode Island properties. In connection with GLP's commitment to consummate the Bally's acquisitions, it also agreed to pre-fund, at Bally's election, a deposit of up to $200M, which will be credited or repaid to GLP at the earlier of closing and December 31, 2023. In addition, Bally's will pay a $9M transaction fee at closing. If all third-party consents and approvals for the acquisition of Lincoln are not timely received, then GLP will instead acquire the real property assets of the Hard Rock Hotel & Casino Biloxi in Mississippi along with Tiverton for total consideration of $635M and a combined annual rent for Tiverton and Biloxi of $48.5M. In that event, GLP will also have the option, subject to receipt of required consents, to acquire the real property assets of Lincoln prior to December 31, 2024 for a purchase price of $771M and additional rent of $58.8M.

16:17 EDT Univar Solutions Mexico signs distribution agreement with Kalsec - Univar Solutions Mexico, a subsidiary of Univar Solutions announced it has expanded its Ingredients & Specialties, or I&S, portfolio through a new exclusive distribution agreement with Kalsec in Mexico. Univar Solutions will become the sole and exclusive distributor in Mexico of Kalsec products, encompassing their Taste and Sensory Solutions, Colors and Food Protection business units. Kalsec's products are derived from natural herbs, spices and vegetables, and are translated into easy-to-use liquid extracts. Kalsec's expertise and resources encompass a full line of natural, innovative products and solutions to meet the challenges faced by food and beverage manufacturers, globally.

16:15 EDT Avista reaches settlement in Washington general rate case - Avista and certain parties to the company's electric and natural gas general rate cases have reached a settlement agreement that has been submitted to the Washington Utilities and Transportation Commission, or UTC, for its consideration. If approved, new rates would take effect in December and December 2023. In addition to Avista, the parties to the electric and natural gas rate cases include the Staff of the UTC, the Public Counsel Unit of the Washington Attorney General's Office, the Alliance of Western Energy Consumers, the NW Energy Coalition, The Energy Project, Walmart, Sierra Club, and Small Business Utility Advocates. All parties, apart from Public Counsel, agreed on the terms of settlement of all issues in Avista's general rate case. The settlement includes, among other things, agreement on electric and natural gas revenue requirement increases for both years of the multi-year rate plan. The recommendation to the Commission by the Staff of the UTC or other parties to approve the multiparty settlement is not binding on the Commission itself. If approved, the settlement agreement is designed to increase annual electric revenues by $38M effective in December and $12.5M effective in December 2023 and increase annual natural gas revenues by $7.5M effective in December and $1.5M effective in December 2023. To mitigate the overall impact of the revenue increases on customers, concurrent with the effective date of this rate case, the settling parties agreed to offset part of the 2022 base rate request with a Residual Tax Customer Credit. The estimated benefits of $27.6M for electric customers and $12.5M for natural gas customers will be incrementally returned over a two-year period from December through December 2024. The electric and natural gas requests are based on a proposed rate of return of 7.03% but the parties did not otherwise agree on an explicit return on equity, cost of debt, or capital structure.

16:12 EDT Parker-Hannifin gives update on UK regulatory clearances related to Meggitt buy - Parker Hannifin welcomes the announcement from the UK's Secretary of State for Business, Energy and Industrial Strategy that he is 'minded-to accept' the statutory competition and national security undertakings provided by Parker as part of its pending acquisition of Meggitt . As previously announced on August 2 the boards of Meggitt and Parker reached agreement on the terms and conditions of a recommended all cash acquisition by Parker of the entire issued, and to be issued, ordinary share capital of Meggitt . This decision is now subject to a public consultation period, which is due to end at 23:45 on July 13. Subject to this consultation, the UK Secretary of State will be in a position to approve the acquisition without further review.

16:10 EDT American Acquisition Opportunity Inc (Class A Stock) trading halted, news pending

16:08 EDT 89bio announces ENTRIGUE trial meets primary endpoint - 89bio announced topline results from ENTRIGUE, the Phase 2 proof-of-concept study evaluating pegozafermin for the treatment of severe hypertriglyceridemia, or SHTG. Treatment with pegozafermin resulted in clinically meaningful and significant reductions in triglycerides, or TG, from baseline across all doses and various subgroups, statistically significant improvements in key markers of cardiovascular risk, reductions in liver fat, and improvements in glycemic control markers. Results showed statistically significant reductions in median TGs from baseline across all dose groups treated with pegozafermin, compared to placebo after eight weeks. Additionally, results were consistent in patients not on background therapy or on background therapy and across various subgroups, including those with the greatest disease burden, such as Type 2 diabetes and baseline TG levels greater than or equal to750 mg/dL. Responder analysis on primary endpoint of TG reduction demonstrated: A significantly higher proportion of patients reached the initial treatment goal of reducing TG less than500 mg/dL on pooled pegozafermin vs. placebo. Treatment with 27mg QW resulted in a significantly higher proportion of patients achieving TG normalization vs. placebo and Greater proportion of patients achieved significant TG reduction of greater than or equal to 50% from baseline vs. placebo. Pegozafermin treatment also resulted in significant improvements compared to placebo and clinically meaningful changes on an absolute basis in non-HDL-C and apo B that are key markers of cardiovascular risk. Patients treated across all doses with pegozafermin also demonstrated an improvement in HDL-C and no change in LDL-C vs. placebo. Pegozafermin treatment resulted in a mean relative reduction in liver fat from baseline at week 8 across all dose groups versus placebo in the substudy of patients with magnetic resonance imaging - proton density fat factor, or MRI-PDFF, and the results are summarized in the table below. A significant proportion of patients responded to therapy with up to 88% and 41% of treated patients vs. 0% of placebo patients achieving a greater than or equal to 30% or a greater than or equal to 50% reduction in liver fat versus baseline, respectively. Results also demonstrated a significant reduction in liver enzymes and an improvement in glycemic control markers in pegozafermin treated patients. Pegozafermin continues to be generally well tolerated with a favorable safety profile across doses consistent with prior studies. In ENTRIGUE, the most commonly reported treatment-related adverse events were nausea, diarrhea, and injection site reactions, all which were classified as mild or moderate. No tremors or transaminase elevation adverse events were observed. There were no drug-related serious adverse events and two Grade 2 treatment-related discontinuations. ENTRIGUE is a randomized, double-blind, placebo-controlled trial that enrolled a total of 85 SHTG patients either on stable background therapy or not on any background therapy treated weekly or every two-weeks with pegozafermin. The trial enrolled an advanced population with high risk of cardiovascular disease as evidenced by mean baseline values of treated patients with TGs of 733 mg/dL, non-HDL-C of 211 mg/dL, 43.5% with HbA1c greater than or equal to 6.5%, and liver fat content of 20.1%.

16:06 EDT Walmart to defend 'robust anti-fraud efforts' after complaint filed by FTC - Walmart issued the following corporate statement in response to a complaint filed by the Federal Trade Commission against the company involving money transfer services: "A narrowly divided Federal Trade Commission brought this factually flawed and legally baseless civil lawsuit after the Chair refused Walmart the due process of hearing directly from the company, and even the Justice Department refused to take this case to court. Claiming an unprecedented expansion of the FTC's authority, the agency seeks to blame Walmart for fraud that the agency already attributed to another company while that company was under the federal government's direct supervision. Walmart will defend the company's robust anti-fraud efforts that have helped protect countless consumers, all while Walmart has driven down prices and saved consumers an estimated $6 billion in money transfer fees." Reference Link

16:05 EDT RealNetworks announces transition of COO Mike Ensing to a strategic advisor role - RealNetworks announced that the COO Mike Ensing will be transitioning to a strategic advisor role at the company, effective July 1. Rob Glaser, Real's Chairman and CEO, said, "Since the beginning of 2020, just before the Pandemic hit, Mike Ensing has been a crucial member of Real's leadership team. First as our interim CFO, and then as our President and COO. I'm deeply grateful and appreciative for everything Mike has done during these turbulent 2 1/2 years to help set Real up for the future. While we're going to miss Mike's fulltime presence, the strong team that Mike has helped us build positions us well for the future."

16:01 EDT Gatos Silver names Andre van Niekerk CFO - Gatos Silver announced the appointments of Andre van Niekerk as Chief Financial Officer effective July 1, 2022 and James Woeller as Vice President, Corporate Development and Business Improvement effective July 16, 2022. Andre brings over 23 years of progressive experience with an excellent track record of success in the mining industry. Mr. van Niekerk joins Gatos Silver from Nevada Copper Corp., where he served as Chief Financial Officer since 2020. He was instrumental in helping to transition Nevada Copper from a development asset to an operating mine and led several successful equity offerings and debt restructurings. Previously, Mr. van Niekerk was Executive Vice President and Chief Financial Officer at Golden Star Resources, an established gold mining company that operates in Ghana. During his 14 years at Golden Star, Andre progressed through various key operational and financial roles with a constant focus on business improvement and value creation. Mr. van Niekerk began his career at KPMG in South Africa and Denver in various advisory and audit roles. He holds bachelor's degrees in accounting from both the University of South Africa and University of Pretoria. Andre is a Certified Public Accountant.

15:20 EDT Takung Art trading resumes

15:00 EDT Takung Art trading halted, news pending

14:33 EDT Square Enix's 'Nier: Automata' has sold over 6.5M units globally - Square Enix (SQNXF) said that 2017 game "Nier: Automata" has shipped and digitally sold 6.5M units worldwide since its launch. The game originally launched for PlayStation 4 (SONY) and PC, and later on received an Xbox One (MSFT) port. The title will be coming to Nintendo Switch (NTDOY) on October 6, 2022. Reference Link

14:08 EDT AeroClean Technologies Inc trading halted, volatility trading pause

13:41 EDT J.B. Hunt, Waymo add Wayfair to autonomous trucking pilot in Texas - J.B. Hunt Transport Services (JBHT) and Waymo (GOOG, GOOGL), the leading autonomous driving technology developer, announced the latest development in their collaboration on autonomous trucking technology will include a pilot delivering goods for J.B. Hunt customer Wayfair (W), one of the world's largest destinations for the home. The latest pilot will span six-plus weeks during July and August and take place along the I-45 corridor between Houston and Dallas, the location of J.B. Hunt and Waymo's original pilot nearly one year ago. It will be the first in-depth transportation of home furnishings retail freight between J.B. Hunt and Waymo Via. "Real-time testing with customers like Wayfair is critical to making autonomous freight movement a viable solution in the future," said Craig Harper, chief sustainability officer and executive vice president at J.B. Hunt. "Every supply chain is unique, so it's important that customers can work alongside J.B. Hunt and Waymo to ensure that advanced autonomous technology will create capacity that meets their needs. Through shared experiences, technology integration and innovative thinking, autonomous technology can help us advance J.B. Hunt's mission to create the most efficient transportation network in North America."

13:02 EDT Emerald Holding acquires Advertising Week event platform from Stillwell - Emerald Holding announced that it has completed the acquisition of all of the assets comprising the business known as Advertising Week from Stillwell Partners. The acquisition of AW signifies another step forward in Emerald's 365-customer engagement strategy of delivering connected, best-in-class experiences through seamlessly integrating in-person events, content and commerce, Emerald said in a statement.

12:48 EDT Qualcomm jumps after analyst says will remain iPhone 5G chip supplier - Shares of Qualcomm (QCOM) jumped after a well-followed analyst said the company's chips are going to be in Apple's (AAPL) next generation iPhones after Apple encountered problems with its own chips. Ming-Chi Kuo, an analyst at TF International Securities, said via Twitter: "My latest survey indicates that Apple's own iPhone 5G modem chip development may have failed, so Qualcomm will remain exclusive supplier for 5G chips of 2H23 new iPhones, with a 100% supply share (vs. company's previous estimate of 20%). Qualcomm's revenue and EPS in 2H23-1H24 will likely beat market consensus thanks to its sole supplier position for 5G chips of 2H23 new iPhones as Apple fails to replace Qualcomm. I believe Apple will continue to develop its own 5G chips, but by the time Apple succeeds and can replace Qualcomm, Qualcomm's other new businesses should have grown enough to significantly offset the negative impacts caused by the order loss of iPhone 5G chips." Qualcomm shares in afternoon trading are up 7%, or $8.48, to $135.66.

12:34 EDT Airbnb codifies ban on parties - Airbnb announced that it is officially codifying a ban on parties as company policy. "At Airbnb, we believe the neighborhoods and communities in which we operate are as important as the Hosts and guests who use our service," the company said. "We know that the overwhelming majority of our Hosts share their homes responsibly, just as the overwhelming majority of guests are responsible and treat their listings and neighborhoods as if they were their own. In turn, we focus on trying to deter the very rare cases of Hosts who do not operate responsibly, or guests who try to throw unauthorized parties. To that end, in August 2020 we announced a temporary ban on all parties and events in listings globally - which at the time was in effect "until further notice." The temporary ban has proved effective, and today we are officially codifying the ban as our policy." Reference Link

12:00 EDT Carvana falls -12.7% - Carvana is down -12.7%, or -$3.85 to $26.49.

12:00 EDT Grove Collaborative falls -23.4% - Grove Collaborative is down -23.4%, or -$1.42 to $4.66.

12:00 EDT Arlington Asset Investment rises 8.1% - Arlington Asset Investment is up 8.1%, or 25c to $3.34.

11:55 EDT Adial Pharmaceuticals CEO sends letter to shareholders - Adial Pharmaceuticals issued a letter to its shareholders from the company's CEO, William Stilley. The letter says in part: "Yesterday, we announced database lock for ONWARD, and today, I want to take this opportunity to personally write to you. Great care was taken to verify and validate the integrity of all data collected during ONWARD, all of which remained blinded throughout. Now that database lock is complete, meaning the dataset has been permanently set, the data has been transferred to the Company's outside, professional statisticians. At this point, only these statisticians have access to the unblinded ONWARD data, and they are now conducting their review. When their analyses is complete, the statisticians will share the unblinded trial data and results with Adial. Adial will then review the unblinded data. In the next several weeks, and most likely by mid-July, we expect to publicly announce the top-line results. Following the announcement, Adial plans to further expand its review of the trial data to determine what other information may be useful to support an application for approval of AD04 to the FDA... After more than three years of work and substantial investment, we seek to confirm and expand on the Phase 2b findings with revelation of the ONWARD results."

11:33 EDT Genasys receives $15.7M U.S. Army LRAD 450XL systems order - Genasys announced a follow-on $15.7M LRAD 450XL systems order from the U.S. Army. Genasys received the order under the Army's Acoustic Hailing Device Program of Record. "The LRAD 450XL provides Soldiers with unparalleled long-range communication, scalable, non-kinetic escalation of force capabilities and mission versatility," said Richard S. Danforth, CEO.

11:07 EDT Bayer's Kerendia recives new grade A recommendations from ADA - Bayer's KERENDIA was recognized by the American Diabetes Association Standards of Medical Care in Diabetes-2022 with a new grade A recommendation for improving cardiovascular outcomes and reducing the risk of chronic kidney disease progression in patients with CKD associated with type 2 diabetes. KERENDIA was approved in the United States based on the results of FIDELIO-DKD, to reduce the risk of sustained eGFR decline, end-stage kidney disease, CV death, nonfatal myocardial infarction and hospitalization for heart failure in adult patients with CKD associated with T2D. The KERENDIA label contains a Warning and Precaution that KERENDIA can cause hyperkalemia. The addendum, titled Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022, was updated based on evidence from the FIDELIO-DKD and FIGARO-DKD Phase III studies as well as the FIDELITY prespecified pooled analysis,1 which comprise the largest cardiorenal outcomes program to investigate the occurrence of fatal and nonfatal CV events and progression of kidney disease in patients with CKD associated with T2D in more than 13,000 patients. The program investigated the impact of finerenone in adults with CKD associated with T2D across a range of disease severity.

10:53 EDT Spirit Airlines: JetBlue offer doesn't address regulatory, board's concerns

10:51 EDT Spirit Airlines reaffirms commitment to merger with Frontier Group

10:28 EDT BASF expands capacity for key specialty amines manufactured in Louisiana - BASF will increase the production capacity for key specialty amines manufactured at its Geismar, Louisiana site. After the completed production capacity expansion of a flexible world-scale production asset by mid-2023, BASF will be able to produce more of its key polyetheramines and tertiary amines marketed under the Baxxodur and Lupragen brands. These assets in North America will complement a global network of specialty amines production plants including those at Verbund sites in Ludwigshafen, Germany, and in Nanjing, China.

10:03 EDT Salient Midstream trading halted, news pending

10:00 EDT Weave Communications falls -5.9% - Weave Communications is down -5.9%, or -20c to $3.19.

10:00 EDT BP Prudhoe Bay rises 7.4% - BP Prudhoe Bay is up 7.4%, or $1.70 to $24.52.

10:00 EDT Rush Street Interactive rises 8.1% - Rush Street Interactive is up 8.1%, or 39c to $5.23.

09:47 EDT ProShares UltraShort Bloomberg Natural Gas falls -4.9% - ProShares UltraShort Bloomberg Natural Gas is down -4.9%, or -$1.58 to $30.51.

09:47 EDT SIGNA Sports United rises 7.0% - SIGNA Sports United is up 7.0%, or 49c to $7.49.

09:47 EDT GreenTree Hospitality rises 11.7% - GreenTree Hospitality is up 11.7%, or 46c to $4.40.

09:38 EDT Globis Acquisition Corp trading halted, volatility trading pause

09:36 EDT Lytus Technologies Holdings Ptv Ltd trading resumes

09:31 EDT Lytus Technologies Holdings Ptv Ltd trading halted, volatility trading pause

09:29 EDT Cardinal, Magellan, Novant launch on-demand drone delivery with Zipline - Three leading U.S. healthcare organizations-Novant Health, Magellan Rx Management, and Cardinal Health-began long-range drone deliveries in North Carolina. Powering this on-demand delivery system is Zipline. Each organization is working independently with Zipline to deliver a variety of products from a distribution center in Kannapolis, North Carolina. Together they are transforming the patient experience and improving when, where, and how care is delivered. Through automated on-demand delivery, organizations and their customers can receive deliveries in as little as fifteen minutes. The North Carolina Zipline distribution center is capable of serving customers within a 7,800 square mile area. "At Cardinal Health, we're committed to working diligently to help ensure our healthcare provider customers have access to the right medication at the right time for their patients, and an effective distribution strategy is required to make this happen," said Josh Dolan, senior vice president, pharmaceutical operations at Cardinal Health. "Through our work with Zipline, we are able to expand our world class distribution services with innovative delivery methods that will help our customers meet their patients' evolving needs - now and in the future."

09:27 EDT Rocket Lab launches CAPSTONE spacecraft, completes first leg of Moon Mission - The company states: "Rocket Lab USA has successfully launched CAPSTONE, a microwave-oven-sized satellite designed to test a new orbit around the Moon for NASA. Thanks to a flawless launch on an Electron rocket to a low Earth parking orbit, CAPSTONE is now in a stable orbit attached to Rocket Lab's Photon Lunar spacecraft bus - a highly capable interplanetary spacecraft that will provide in-space transportation to set CAPSTONE on a course for the Moon. From the initial parking orbit that CAPSTONE is in now, Photon Lunar's HyperCurie engine will perform a series of orbit raising maneuvers over five days. The HyperCurie engine will ignite periodically to increase Photon's velocity, stretching its orbit into a prominent ellipse around Earth. Six days after launch, HyperCurie will ignite one final time, accelerating Photon Lunar to 24,500 mph and setting it on ballistic lunar transfer. Within 20 minutes of this final burn, Photon will release CAPSTONE into space for the first leg of the CubeSat's solo flight. CAPSTONE's journey to NRHO is expected to take around four months from this point. Assisted by the Sun's gravity, CAPSTONE will reach a distance of 963,000 miles from Earth - more than three times the distance between Earth and the Moon - before being pulled back towards the Earth-Moon system. This sinuous track follows dynamic gravitational contours in deep space."

09:24 EDT Wrap Technologies shares new body cam footage demonstrating BolaWrap - Wrap Technologies shared new agency body cam footage demonstrating another successful outcome from the deployment of the BolaWrap Remote Restraint device. On June 3, 2022, two officers of the Northern York County Regional Police Department in Pennsylvania responded to a domestic dispute. When the officers arrived on-scene, the subject responded with hostility and attempted to initiate a physical altercation. After various threats and erratic behavior from the subject and multiple requests by the officers for compliance, the officers were able to coordinate a plan to use the BolaWrap to restrain the subject. The BolaWrap was deployed to the subject's arms and immediately redirected the subject's attention and de-escalated the situation. The officers were able to swiftly contain the subject with handcuffs without the need for other tools or higher levels of physical force. The subject was safely taken into custody and transported to a nearby hospital for a mental health evaluation.

09:23 EDT Tyler Technologies in pacts in Lima, Ohio, no terms - Tyler Technologies announced that it has signed an agreement in Lima, Ohio. The agreement is with the Lima Police Department for Tyler's Enterprise Public Safety suite, powered by New World , and the Lima Municipal Court, Clerk of Court and Adult Probation department for Tyler's Enterprise Justice suite, powered by Odyssey. The city of Lima is currently using a legacy public safety and court case management system that is based on older technology and no longer serves the business processes of the police, court, and probation departments. The city selected Tyler as it provides solutions for all aspects of the city's police, court, and probation business, delivering the necessary functional requirements without having to use subcontractors or third parties. For the police department, that includes Tyler's Enterprise Computer Aided Dispatch , Enterprise Law Enforcement Records, and Enterprise Police and Fire Mobility solutions. For the municipal court, that includes Tyler's Enterprise Justice and Enterprise Supervision solutions.

09:22 EDT Creative Realities announces partnership with Strike Ten Entertainment - Creative Realities and Strike Ten Entertainment announced a marketing partnership designed to help bowling centers grow their revenues via the role digital signage will play in transforming the food and beverage experience across bowling centers nationwide for proprietors and consumers. The marketing partnership provides a platform for Creative Realities to showcase how its offering can help the business of traditional bowling centers for proprietors and enhance the customer experience with modern digital displays.

09:18 EDT JetBlue highlights opposition of Spirit Airlines-Frontier Group merger proposal - JetBlue (JBLU) highlighted the recent support in favor of its "clearly superior" offer to acquire Spirit (SAVE). Institutional Shareholder Services, or ISS, issued late yesterday an updated report acknowledging that clients may find the modified JetBlue proposal "preferable" to the Frontier (ULCC) offer for Spirit and may therefore choose to vote against the Frontier transaction at Spirit's upcoming special meeting, despite ISS's inability to change its official recommendation. Additionally, Spirit shareholder TIG Advisors publicly declared that it will vote against the Frontier merger at the Spirit special meeting, and sent a letter to the Spirit Board in which it said, "We believe JetBlue's acquisition proposal is the far superior outcome for Spirit and its shareholders, given its all-cash bid eliminates execution risk and maximizes certainty of value." In its new report, ISS, citing the recent changes to JetBlue's offer, noted that "the enhancements by JetBlue may be enough to offset the potential upside of the proposed merger with Frontier." ISS further noted that "the gap between the headline offers has not only widened since Spirit and Frontier modified the deal terms late last week, but the prepayment dividend and the reverse termination fee accompanying the JetBlue offer are now more favorable for Spirit shareholders than the corresponding provisions accompanying the Frontier offer. At the same time, the addition of the ticking fee in the JetBlue offer - a provision without a counterpart in the Frontier offer - provides a further level of regulatory risk mitigation."

09:17 EDT Digital Ally announces three 2022 patents - Digital Ally, announces three 2022 patent issuances. These issued patents continue to demonstrate the Company's commitment to engineering innovative evidence capturing and safety technology for law enforcement, first responders and commercial fleets. "We are proud to be the patent leader in evidence capture and safety technology," said Stan Ross, CEO of Digital Ally, adding, "Every day, our engineers and entire staff continue to develop new technology and invest in future R&D that put our customers in the best possible position for safety and security." Issued patents include: Patent # 11,244,50: A system for tracking a fleet of vehicles and analyzing a driver associated with the fleet of vehicles. Patent # 11,290,693: System, method, and media for providing automatic recording of an event. Patent # 11,310,399: A portable video and imaging system includes a camera for capturing video of an event, and a video recording device for recording the captured video of the event.

09:14 EDT EnWave sells 10kW Machine to Fungaria Snack - EnWave Corporation announced that it has received a signed purchase agreement from Fungaria Snack for a 10kW Radiant Energy Vacuum dehydration machine to be located at their production facility in Budapest, Hungary. The 10kW machine was commissioned in February 2021 as part of a technology evaluation, and will be utilized for the development and commercialization of premium fruit and vegetable snacks for the Hungarian market.

09:13 EDT Mobiquity selected by GroveToekn as data, programmatic ad provider - Mobiquity Technologies announced it has been selected by GroveToken as its data and programmatic advertising provider in front of their meeting with the Dubai Royal Family to discuss the future of farming practices through Aeroponics and Hydroponics. GroveToken is creating awareness for their new eco-friendly digital currency and will be meeting with the Royal Family of Dubai later this week to educate them on the abilities of Grove to produce tokens cleaner and with less electronic wastage than other digital currencies. John Ghemrawi, CEO of Grove Token said, "GroveToken is one of the few Crypto projects that combines virtual currency with physical business investments. Grove is here to make a difference in how the general investors perceive crypto whilst creating wealth with a conscience. Keeping our planet in mind, Grove is focused on creating a long-lasting business for generations to come. Invest in sustainability- invest in our future."

09:11 EDT Velo3D announces acquisition of Sapphire family printer - Velo3D announced Knust-Godwin, a precision contract manufacturer, has received a Sapphire XC to expand its metal additive manufacturing, or AM, capabilities. The acquisition of an additional Sapphire family printer from Velo3D further expands Knust-Godwin's additive manufacturing offering by unlocking high-volume production and lower costs for its largest customers. Knust-Godwin's Sapphire XC will reside in its Katy, Texas facility, is calibrated for Inconel 718, and is fully compatible with its other Sapphire Inconel 718 printers, so as customers scale up production, they can take advantage of the Sapphire XC's benefits. Since its release in December 2021, there has been extensive demand for the Sapphire XC. The demand is largely driven by the Sapphire XC's ability to lower production costs by up to 75% and produce parts that are 500% larger in volume compared to the company's Sapphire system. Knust-Godwin is the first of Velo3D's network of contract manufacturers to receive a Sapphire XC.

09:09 EDT C3.ai awarded on $90M HHS agreement - The U.S. Department of Health and Human Services, or HHS, has awarded a joint $90M, five-year agreement to Citi, the software services and product company, and C3 AI, the Enterprise AI application software company, through its partnership with Carahsoft. The blanket purchase agreement, or BPA, called "Solutioning with Holistic Analytics Restructured for the Enterprise (SHARE)," will accelerate enterprise AI deployments across the entire HHS, which includes the National Institutes of Health, or NIH, the FDA, and the Centers for Disease Control and Prevention, or CDC.

09:07 EDT Agilon Health appoints Denise Zamore as first Chief Legal Officer - agilon health announced the appointment of Denise Zamore as the company's first Chief Legal Officer and Secretary to the agilon health Board of Directors effective August 1, 2022. Zamore will become a member of the executive leadership team, reporting to Steve Sell, CEO, and will lead the company's legal function.

09:05 EDT Nuvve Holding and Switch partner to develop V2G GIVeTM platform - Nuvve Holding and Switch, a global leader in standardized electric charging management and maintenance software, are partnering to integrate Nuvve's vehicle-to-grid, or V2G, GIVeTM platform with Switch's charging management platform for operations and maintenance, or O&M. The strategic partnership will allow the global transportation industry to intelligently make the switch to EVs by combining Nuvve's V2G expertise in energy management for vehicles, fleets, connected buildings, and grid services with Switch's EV charging platform. The combination is intended to achieve greater efficiencies, interoperability, and a seamless customer experience. Standardizing operating languages of critical software solutions is a precedent for best-in-class platform offerings across the industry.

09:04 EDT JetBlue Products extends long-term relationship with Allianz Partners USA - JetBlue Travel Products, a subsidiary of JetBlue Airways announced a multi-year partnership extension with Allianz Partners USA, bolstering their relationship for the busy summer season and beyond. The partnership provides JetBlue customers the ability to protect both their flights and vacation packages with travel insurance. The contract re-affirms Allianz Partners as the official travel insurance provider of JetBlue Airways and JetBlue Travel Products. JetBlue Travel Products also announced that JetBlue Vacations Travel Experts will now be able to offer Allianz Travel Insurance plans over the phone to customers purchasing JetBlue Vacations packages. Allianz Travel Insurance products* offered by JetBlue Vacations includes Allianz's Epidemic Endorsement, which covers travelers for cancellations, interruptions and medical emergencies due to illness with COVID-19 or a future epidemic.

09:03 EDT JanOne announces completion of work for improved formulation of JAN101 - JanOne announced that work has been completed by Maureen Donovan at the University of Iowa that will allow for an improved formulation of JAN101. JAN101, formerly known as TV1001SR, is a potential treatment for peripheral artery disease, or PAD, a vascular disease that affects more than 8.5 million people in the U.S. and more than 60 million people worldwide. While JAN101 has been used successfully in clinical trials to reduce pain and improve nerve function, JanOne has continued to work on optimizing the formulation. This new formulation will be used by CoreRx, JanOne's GMP manufacturer, to manufacture clinical supply and validate the JAN101 manufacturing process for the Company's upcoming pivotal clinical trial. JanOne expects to begin the manufacturing and validation process in the near future.

09:02 EDT Wheels Up, Hertz partner on new electric vehicle offerings - Wheels Up Experience (UP) and Hertz (HTZ) announced a new strategic partnership to give Wheels Up members access to Hertz's industry-leading electric vehicle offerings and new, premium benefits. Wheels Up members have access to a variety of high-end vehicles, including Tesla and Polestar models from the largest rental fleet of electric vehicles in North America. The EV models are available for rent from Hertz at 111 private airports, with plans to expand to more than 500 private airports in the coming months. Members also receive complimentary President's Circle top-tier status in the award-winning Hertz Gold Plus Rewards loyalty program. President's Circle is Hertz's highest loyalty membership tier and includes an elevated selection of vehicles, guaranteed upgrades, dedicated customer support and more bespoke benefits.

09:01 EDT U.S. Steel provides update on metallics strategy - U.S. Steel (X) announced it would expand its low-cost iron ore competitive advantage and increase its self-sufficiency by supplying domestic feedstock to its growing fleet of electric arc furnaces, or EAFs. The company expects related improvements to its capital and carbon intensity and financial performance from anticipated future internal and external EAF demand. U. S. Steel plans to break ground in Fall 2022 at one of its two Minnesota Ore Operations facilities, Keetac or Minntac, to construct a system dedicated to producing DR-grade pellets. This will enable one of the company's existing pelletizing plants to not only create DR-grade pellets but also maintain the optionality to continue producing blast furnace-grade pellets. The company does not expect the approximately $150M DR-grade pellet investment to change the 2022 capital spending budget and will continue to prudently manage future capex in-line with its strategic priorities. U. S. Steel signed a non-binding letter of intent with SunCoke Energy (SXC), a raw material processing and handling company, setting forth the preliminary terms for a potential arrangement under which SunCoke would acquire the two blast furnaces at Granite City Works and build a 2M ton granulated pig iron production facility. Upon completion of the proposed facility, SunCoke would supply U. S. Steel access to 100% of the pig iron production for the next ten years. U. S. Steel intends to supply the needed iron ore to be used to produce the pig iron. Because the iron ore would come from U. S. Steel's own mines, the Company would realize a significant cost advantage. This pig iron could be used by EAFs and is expected to supply U. S. Steel's growing fleet of EAFs. The proposed transaction is contingent upon several conditions, including the negotiation and execution of a definitive agreement, approval by the U. S. Steel board of directors, and receipt of all appropriate regulatory approvals. There can be no assurance as to the final terms of the proposed transaction, that the conditions will be satisfied, or that the proposed transaction will be completed. U. S. Steel recently announced an investment in a pig iron caster at Gary Works in Indiana. The approximately $60M investment will produce up to 500,000 tons of pig iron annually and provide a critical raw material input for the company's EAFs. Once complete, the Gary pig iron project is expected to provide nearly 50% of Big River Steel's ore-based metallics needs, contribute over $30M of run-rate enterprise EBITDA benefits and deliver an internal rate of return in excess of 30%. Pig iron production at Gary Works should begin in the first half of 2023.

08:54 EDT Medigus announces ScoutCam announced a JDA with an aviation company - Medigus announced that ScoutCam announced a Joint Development Agreement, JDA, with a global leading defense and aviation company. According to the JDA, the defense and aviation company will utilize ScoutCam's proprietary visualization technology for in-flight monitoring of various components of its fleet of aerial vehicles, as well as serve as a replacement for manual pre-and post-flight visualization inspections of the aerial platforms. The multi-year partnership established by the JDA combines various technical aspects of the relationship between ScoutCam and the customer and ensures future supply of ScoutCam's monitoring solutions to the aerial vehicles.

08:48 EDT SunCoke Energy announces non-binding LOI with U.S. Steel - SunCoke Energy (SXC) announced it has entered into a non-binding letter of intent, or LOI, with United States Steel Corporation (X) that sets out the principal terms and conditions upon which SunCoke would process iron ore supplied by U.S. Steel to manufacture granulated pig iron for U. S. Steel on a 10 year initial term. The parties are currently assessing capital and other project requirements, with the goal of entering into definitive agreements once these assessments are complete. The agreements would include SunCoke's acquisition of blast furnaces and other ancillary assets at U.S. Steel's Granite City Works. The permitting and construction of the contemplated granulated pig iron facilities with a combined annual production capacity of 2.0 million tons is expected to take approximately 2 years. SunCoke will continue to operate its Granite City coke plant, supplying coke to the Granite City Works blast furnaces.

08:45 EDT SunCoke Energy enters into non-binding LOI with U.S. Steel - SunCoke Energy announced it has entered into a non- binding letter of intent, or LOI, with United States Steel Corporation that sets out the principal terms and conditions upon which SunCoke would process iron ore supplied by U. S. Steel to manufacture granulated pig iron for U. S. Steel on a 10 year initial term. The parties are currently assessing capital and other project requirements, with the goal of entering into definitive agreements once these assessments are complete. The agreements would include SunCoke's acquisition of blast furnaces and other ancillary assets at U. S. Steel's Granite City Works. The permitting and construction of the contemplated granulated pig iron facilities with a combined annual production capacity of 2.0 million tons is expected to take approximately 2 years. SunCoke will continue to operate its Granite City coke plant, supplying coke to the Granite City Works blast furnaces.

08:42 EDT Aerojet Rocketdyne's Lichtenstein issues statement ahead of special meeting - Aerojet Rocketdyne Holdings Executive Chairman Warren Lichtenstein, who collectively with his affiliates and the participants in his solicitation owns approximately 5.6% of the Company's outstanding shares, issued the below statement ahead of a special meeting of shareholders scheduled to be held on June 30. As a reminder, Mr. Lichtenstein is seeking support on the GREEN Proxy Card to elect his refreshed slate of highly qualified candidates to the Company's Board of Directors . Mr. Lichtenstein commented: "Aerojet Rocketdyne's viability as a functioning and sellable business hangs in the balance at this week's Special Meeting. If shareholders elect Eileen Drake's slate of director candidates, they will be solidifying the power of a rogue Chief Executive Officer who refuses to acknowledge the Company's financial and operational deterioration and has not put forth a strategic plan. Shareholders should not be fooled by Ms. Drake's attempts to downplay the last 18 months of evident cash flow issues, customer complaints, employee attrition and program performance lapses. Her unwillingness to pre-release second quarter results signals that the Company is, in fact, reeling from neglect. These problems need to be immediately addressed by a credible Chief Executive Officer and an engaged Board, or else hundreds of millions - if not billions - of dollars in value will be destroyed. Fortunately, Mark Tucker and the rest of our refreshed slate have diagnosed Aerojet Rocketdyne's vulnerabilities and outlined a comprehensive fix-and-repair plan that targets at least $65 per share within three years."

08:39 EDT Quantum Computing announces inclusion in Russell Microcap Index - Quantum Computing has joined the Russell Microcap Index, following the conclusion of the 2022 Russell indexes annual reconstitution, effective June 27th. "Joining the Russell Microcap Index represents another important milestone for QCI, after our recent acquisition of QPhoton to transform QCI into a full-stack quantum computing company," said Robert Liscouski, CEO of QCI. "We believe this listing reflects that we've arrived at an inflection point in terms of growth and development with the combination of our quantum software and hardware solutions. We welcome this greater visibility in the investment community as we continue to deliver value and results for non-quantum experts - truly democratizing quantum computing."

08:38 EDT Thoughtworks to buy privately-held, Brazilian-based Handmade Design, no terms - Thoughtworks announced its intent to acquire privately-held, Brazilian-based Handmade Design Handmade Design was founded in 2015 with a core value built around "learning by doing together". This core value is reflected in the company's approach to researching to discover clients' true needs, aligning these insights with business goals and then allowing them to inform every step of the agile process from design to delivery. Today, Handmade has about 50 employees based primarily in Sao Paulo, Brazil with expertise across the design discipline and a strong capacity to perform strategic work in remote settings. Handmade Design has delivered more than 100 solutions to address the business challenges of large companies in Brazil such as Petlove, iFood, Santander and Itau...The close of the acquisition will see Handmade Design bolster and enhance the Thoughtworks customer experience, product and design service line in Brazil. Luis Felipe Fernandes, the CEO & co-founder, will report to Marta Saft, managing director, Thoughtworks Brazil. The acquisition is expected to close in the third quarter of Thoughtworks' fiscal year 2022, subject to customary closing conditions. Financial details are not being disclosed.

08:32 EDT Steel Dynamics and Aymium form SDI Biocarbon Solutions joint venture - Steel Dynamics announced the creation of a strategic joint venture with Aymium, a leading producer of renewable biocarbon products. Steel Dynamics owns 55% of the joint venture, with Aymium owning the remaining 45%. The entity will operate under the name SDI Biocarbon Solutions. Initial plans for the joint venture include the construction and operation of a biocarbon production facility to supply Steel Dynamics' electric arc furnace steel mills with a renewable alternative to fossil fuel carbon using Aymium's patented technology. The initial facility's production capability is expected to be more than 160,000 metric tons per year, for an estimated capital investment of $125M-$150M. The facility is planned to begin operations late 2023.

08:26 EDT EHang announces strategic partnership with ABC Guangzhou Branch - EHang Holdings announced it has entered into a strategic partnership with the Guangzhou Branch of Agricultural Bank of China, ABC Guangzhou Branch, one of the world's 10 largest commercial banks. ABC Guangzhou Branch is expected to provide EHang with comprehensive banking services, including indicative credit facilities of RMB1 billion, to support EHang's operations in China. This partnership with ABC Guangzhou Branch will offer tremendous support for the Company's long-term sustainable business growth, including on R&D, manufacturing, and sales and operations. "We are very pleased to enter into a strategic partnership with ABC Guangzhou Branch," said Huazhi Hu, Founder, Chairman and Chief Executive Officer of EHang. "The RMB1 billion indicative facilities for cooperation will further diversify our funding channels and facilitate our financial flexibility and liquidity to support the continuous execution of our strategic plans and drive our growth momentum in the long run."

08:22 EDT CSW Industrials appoints Motsenbocker to board of directors - CSW Industrials announced that its Board of Directors has elected Anne Motsenbocker as an independent director. In her new role, Motsenbocker has also been appointed as a member of the Audit Committee and the Compensation and Talent Development Committee of the Company's Board. On June 27, 2022, current Board member Debra von Storch notified the Company of her intent to not stand for re-election at the 2022 annual meeting of shareholders. von Storch's decision to not stand for re-election does not result from any disagreement with the Company on any matter. Following this notification, Swartz was elected Chairman of the Audit Committee, effective June 27, 2022.

08:20 EDT Canadian National to invest $25M in Louisiana in 2022 - CN announced plans to invest approximately $25M in Louisiana in 2022. This includes investments in technology, capacity, rolling stock units and company-wide decarbonization initiatives, as well as network improvements. "We continue to make significant investments in our network, technology, and capacity. We are building the premier railroad of the 21st century to do even more for our customers, railroaders, shareholders, and the communities in which we operate." - Sean Finn, Executive Vice-President, Corporate Services and Chief Legal Officer of CN. Maintenance program highlights include: Replacing 4 miles of rail; Installing approximately 20,000 new railroad ties; Rebuilding 16 road crossing surfaces; and Maintenance work on bridges, culverts, signal systems, and other track infrastructure

08:18 EDT Certara introduces Simcyp Discovery Simulator - Certara announced the release of Simcyp Discovery Simulator, a new software designed for scientists working in small molecule drug discovery and translational research. "We are pleased to offer our new Simcyp Discovery Simulator to help identify and move forward the most promising new drug candidates for further investigation," said William Feehery, Ph.D., CEO of Certara. "The failure rate from preclinical to clinical studies is high with only a third of drugs entering into human testing. With Simcyp Discovery, scientists can apply PBPK earlier in the development process to better inform critical decisions and reduce risk of drug failure."

08:17 EDT VBI Vaccines presents data from HBV study at ILC and EASL - VBI Vaccines announced that new data from a follow-up analysis of a subset of participants from the pivotal Phase 3 study of the Company's 3-antigen prophylactic hepatitis B vaccine, were presented in an oral presentation at The International Liver Congress 2022, the Annual Meeting of the European Association for the Study of the Liver , which took place on June 26. Timo Vesikari, M.D., Ph.D., Professor Emeritus and Director of the Nordic Vaccine Research Network in Finland, and principal investigator of the PROTECT and CONSTANT Phase 3 clinical studies of VBI's 3-antigen HBV vaccine, highlighted data from his investigator-initiated analysis that evaluated duration of immune response approximately 2.5 years after completion of vaccination. Immunogenicity was assessed using frozen sera samples from a subset of participants who had been enrolled at five clinical sites in Finland as part of PROTECT. In the follow-up analysis, participants in PROTECT who received VBI's 3-antigen HBV vaccine had 5.5-fold higher mean anti-HBs titers and a higher seroprotection rate compared to those who received Engerix-B. Additionally, 72.9% of participants who received VBI's 3-antigen HBV vaccine retained anti-HBs titers greater than or equal to 100 mIU/mL compared to 32.6% of those who received Engerix-B. "In the PROTECT study, more adults were protected with VBI's 3-antigen vaccine than with the single-antigen vaccine, and in this follow-up analysis we continued to see the benefit of the 3-antigen vaccine," said Francisco Diaz-Mitoma, M.D., Ph.D., VBI's Chief Medical Officer. "As we focus on the road ahead and our commitment to broadening access to this vaccine in Europe and North America, we continue to believe that our 3-antigen vaccine has the potential to be a meaningful new intervention in the public health battle to eradicate hepatitis B."

08:16 EDT Brainsway announces insurance coverage by Israeli Ministry of Health - BrainsWay announced that, for the first time, the Israeli Ministry of Health has approved coverage applicable to its Deep TM system for the treatment of depression. The inclusion of the treatment within Israel's health basket of essential medical services means that the country's health funds must now make the treatment available to qualifying patients free of charge. Qualifying patients include adults over the age of 21 with depression who have either not responded to two prior antidepressants, or who are intolerant to other treatment alternatives. Coverage may be provided for up to 40 treatment sessions, which are to be administered in hospitals.

08:14 EDT Silicon announces expiration of HSR waiting period for MaxLinear acquisition - Silicon Motion Technology (SIMO) announced the expiration of the waiting period under the Hart-Scott-Rodino, HSR, Antitrust Improvements Act of 1976, as amended, with respect to the previously announced agreement under which MaxLinear (MXL) will acquire Silicon Motion in a cash and stock transaction in which each American Depositary Share of Silicon Motion, which represents four ordinary shares of Silicon Motion, will receive $93.54 in cash and 0.388 shares of MaxLinear common stock, and each ordinary share of Silicon Motion will receive $23.385 in cash and 0.097 shares of MaxLinear common stock. The expiration of the HSR waiting period occurred at 11:59 p.m. ET on June 27, 2022, which was a condition to the closing of the pending transaction. The closing of the transaction is subject to the satisfaction of the remaining customary closing conditions, including approval by Silicon Motion's security holders and the receipt of regulatory approval in the People's Republic of China.

08:12 EDT Ontrak CEO Mayhew to step down Executive Chairman Peizer to fill post - Ontrak announced Jonathan Mayhew will step down as Chief Executive Officer effective August 12. Mayhew cited family health reasons for his departure. He intends to be available to support the Company through the end of October 2022. Terren Peizer, Founder and Executive Chairman, will take over as CEO upon Mr. Mayhew's departure. Mr. Peizer was most recently CEO until April 2021 when he became Executive Chairman. He will continue to serve as Chairman of the Board of Directors. As CEO, Mr. Peizer will focus on the Company's strategic direction, capital formation process and other corporate initiatives. The Company also announced the following promotions of existing executives and organizational changes, which are effective immediately. Brandon LaVerne, current Chief Financial Officer , has been promoted to Co-President and Chief Operating Officer with added responsibilities over the clinical, technology, and product operations of the Company. James Park, current Chief Accounting Officer, has been promoted to Chief Financial Officer and assumes responsibilities over finance, human resources, legal, medical economics, and investor relations, reporting to Mr. LaVerne. Mary Lou Osborne, current Chief Customer Officer, has been promoted to Co-President and Chief Commercial Officer. Ms. Osborne joined Ontrak in August 2021 from Aetna and will continue to focus on growing Ontrak's pipeline, current Ontrak and LifeDojo customer relationships, and go-to-market strategy. As a result, marketing and business development now report to Ms. Osborne.

08:10 EDT Joann announces addition of Coleman to board of directors - JOANN announced Brian Coleman as the newest member of its Board of Directors. Coleman, Vice President at Leonard Green & Partners, was also appointed to JOANN's Nominating & Governance and Compensation Committees, effective June 24, 2022.

08:08 EDT Endra Life Sciences enhances TAEUS System intellectual property portfolio - ENDRA Life Sciences announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 titled "Broadband Applicator for Thermoacoustic Signal Generation." The '272 patent protects TAEUS' radiofrequency applicator for optimizing the delivery of RF energy to tissue. Notably, the RF applicator utilizes a broad bandwidth, which reduces TAEUS' sensitivity to tissue variation and temperature. The '272 patent will serve as the parent patent for future patent applications prosecuted in China and Europe. "We are pleased with the issuance of our 28th patent in the United States, which supports our strategy to develop optimized thermoacoustic imaging systems, and to broaden the potential applications for our proprietary TAEUS technology in areas with unmet clinical needs," stated ENDRA's Chairman and Chief Executive Officer Francois Michelon. "We continue to strengthen our intellectual property portfolio to protect our novel technology in key global markets. Our IP portfolio currently includes 48 patents issued globally."

08:06 EDT Walgreens Boots Alliance ends strategic review, to keep ownership of Boots unit - Walgreens Boots Alliance announced its decision to keep its Boots and No7 Beauty Company businesses under its existing ownership. This marks the conclusion of the review that began in January in line with the company's strategic priorities. "WBA has been encouraged by productive discussions held with a range of parties, receiving significant interest from prospective buyers. However, since launching the process, the global financial markets have suffered unexpected and dramatic change. As a result of market instability severely impacting financing availability, no third party has been able to make an offer that adequately reflects the high potential value of Boots and No7 Beauty Company. Consequently, WBA has decided that it is in the best interests of shareholders to keep focusing on the further growth and profitability of the two businesses. The decision to retain the businesses has also been supported by the ongoing strong performance and growth of Boots and No7 Beauty Company, which have exceeded expectations despite challenging conditions. Boots is the UK's leading health and beauty retailer and benefits from its unique position as one of the most trusted and well-respected brands in the country. Since the formation of WBA at the end of 2014, the Company has significantly invested in Boots and No7 Beauty Company. Given their unmatched assets and unparalleled potential, Walgreens Boots Alliance will continue investing in the future of these two businesses," the company said. Walgreens Boots CEO Rosalind Brewer added: "We have now completed a thorough review of Boots and No7 Beauty Company, with the outcome reflecting rapidly evolving and challenging financial market conditions beyond our control. It is an exciting time for these businesses, which are uniquely positioned to continue to capture future opportunities presented by the growing healthcare and beauty markets. The Board and I remain confident that Boots and No7 Beauty Company hold strong fundamental value, and longer term, we will stay open to all opportunities to maximize shareholder value for these businesses and across our company."

08:05 EDT Wejo to leverage connected vehicle data in Europe to enable end-to-end insurance - Wejo Group (WEJO), announced a collaboration with Ford (F) in Europe which gives Wejo access to personalized connected vehicle data from Ford vehicles across the continent. This supports the provision of data and insights to insurance providers that leverage user-based intelligence for end-to-end insurance. Insurance providers, in turn, can leverage the data to better understand driving behaviors and to drive efficiencies, including by minimizing fraud. "Providing actionable data insights to insurance providers is another example of how Wejo is expanding into additional markets and demonstrating new use cases for OEMs and insurance companies to monetize connected vehicle data for good," said Richard Barlow, founder and CEO, Wejo. "We will continue to work with partners like Ford and other vehicle OEMs to look beyond insurance to identify all the use cases for connected vehicle data." As part of this collaboration, Wejo leverages Ford's end-to-end data consent process through which the insurance company gains consent from the customer to access the personalized vehicle data such as vehicle location, speed and mileage. Once provided, that consent is then passed back to Ford through Wejo to release the data for analysis and insight. The connected vehicle data is then passed back to the insurer to establish usage-based end-to-end car insurance policies that are appealing to the customer based on their safe driving or limited mileage.

08:02 EDT Circle Internet Financial announces custody partnership with NYCB - Circle Internet Financial, a global digital financial technology firm and the issuer of USD Coin, has announced a custody partnership with New York Community Bancorp, or NYCB. Under this agreement, NYCB's bank subsidiary, New York Community Bank, will become a custodian for USDC reserves. Additionally, the two organizations will work together to create strategies utilizing Circle blockchain and stablecoin solutions to promote access to low-cost financial solutions for underserved and unbanked communities. Additionally, the plan will develop support for Minority-owned Depository Institutions, or MDIs, where additional reserves may be held. New York Community is the first community bank approved by Circle to serve as a custodian for USDC reserves.

08:01 EDT II-VI obtains all regulatory approvals to complete acquisition of Coherent - II-VI Incorporated (IIVI) announced that II-VI has obtained antitrust clearance from the State Administration for Market Regulation of the People's Republic of China for II-VI's pending acquisition of Coherent (COHR). The clearance decision from SAMR satisfies the closing condition set forth in the previously announced merger agreement regarding the receipt of antitrust approvals. II-VI expects the closing of its acquisition of Coherent to occur on or about July 1, 2022. Under the terms of merger agreement, each share of Coherent common stock will be converted into the right to receive $220.00 in cash and 0.91 of a share of II-VI common stock upon the completion of the transaction.

07:46 EDT Sutro Biopharma up 24.5% in pre-market after Astellas Pharma deal - Shares of Sutro Biopharma (STRO) are up 24.5% at $5.39 in pre-market trading after the company announced a worldwide, strategic collaboration and licensing agreement focused on the discovery and development of novel immunostimulatory antibody-drug conjugates with Astellas (ALPMY) overnight that includes an upfront cash payment of $90M.

07:43 EDT Red Cat's Skypersonic inspects industrial plants with drone - Industrial drone company Skypersonic - part of publicly traded drone company Red Cat - visually inspected the interior of a fully operational utility plant in Turin, Italy, using a drone controlled from Orlando, Fla., 4,800 miles away. The Orlando-based pilot - Drew Camden, president of Red Cat subsidiary Rotor Riot - had no advance knowledge of the Iren district heating-network plant in Turin through which he piloted the Skypersonic "Skycopter" drone. This special drone can be piloted without the aid of GPS, a fundamental system for piloting conventional drones outdoors but that is not available indoors, under bridges, in tunnels and other enclosed spaces. "We learned much from this historic flight controlled from an ocean away, which is actually our third trans-Atlantic flight," said Giuseppe Santangelo, Skypersonic CEO. "Most importantly, we learned that an internet connection via a mobile phone in the vicinity of the drone is all that is needed to remotely pilot a drone from virtually anywhere - in fact, up to 8,000 miles away. The previous two flights had relied on a more sophisticated, non-mobile internet connection. We also learned that it is possible to navigate a very dense and complex interior environment from another continent using this easily configurable set-up."

07:39 EDT G1 Therapeutics announces addition of Lee to board of directors - G1 Therapeutics (GTHX) announced the appointment of Jacks Lee to its Board of Directors. For more than 30 years, Lee has developed experience in manufacturing and supply chain management in the life sciences industry. Lee currently serves as Senior Vice President - Manufacturing & Supply of Merck & Co (MRK).

07:37 EDT Enovix Mobility announces it has broadened leadership team - Enovix Corporation announced it has broadened its leadership team responsible for bringing its cell technology to the Electric Vehicle, EV, market. Enovix Mobility will be led by James Wilcox, PhD. Dr. Wilcox joined Enovix in 2008 as part of the core engineering team that developed the company's proprietary stacked cell architecture. Enovix also hired Spencer Gore as Head of EV products. Dr. Wilcox and Gore will join Pat Donnelly, Vice President, Strategic Business Development, on the Enovix Mobility leadership team, and together, they will execute the company's EV product and business strategy.

07:35 EDT Apyx Medical announces receipt of FDA 510 clearance for Renuvion Dermal - Apyx Medical previously announced the receipt of 510 clearance from the FDA for the use of the Renuvion Dermal handpiece for specific dermatological procedures for the treatment of moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II or III. Branded as Facial Renewal, this treatment for wrinkle-reduction provides patients with an effective and nonsurgical option for smoothing and contracting the skin in one procedure.

07:32 EDT Jazz Pharma announces results from Phase 3 RELEASE MSS1 trial - Jazz Pharmaceuticals announced top-line results from the Phase 3 RELEASE MSS1 trial evaluating nabiximols oromucosal spray on clinical measures of spasticity in individuals with multiple sclerosis, or MS. The RELEASE MSS1 trial did not meet the primary endpoint of change in Lower Limb Muscle Tone-6 between baseline and Day 21, as measured by the Modified Ashworth Scale, or MAS. Nabiximols oromucosal spray is a complex botanical mixture formulated from extracts of the cannabis sativa plant and contains the cannabinoids delta-9-tetrahydrocannabinol and cannabidiol, as well as other cannabinoid and non-cannabinoid components. Data from the RELEASE MSS1 trial will be submitted for presentation at a future medical meeting.

07:30 EDT Land's End announces $50M share repurchase authorization - Lands' End announced that its Board of Directors has authorized the repurchase of up to $50M of the Company's common stock through February 2, 2024, the conclusion of its fiscal year 2023. Under the program, the Company may purchase its shares from time to time in the open market, in privately negotiated transactions, or by other means in accordance with federal securities laws. Simultaneously, the Company continues to explore debt refinancing options as part of its ongoing commitment to drive stockholder value. Jim Gooch, President and Chief Financial Officer of Lands' End, said, "This share repurchase authorization exemplifies both the Board's and management's confidence in the strength of our business model and our long-term growth prospects. We believe a balanced capital allocation strategy supported by a share repurchase program, optimized debt structure and continued investment in our growth strategies will drive long-term value for our stockholders." The Company expects that purchases will be funded through existing cash on hand, cash from operations, borrowings under its asset-based senior secured credit facility or a combination of the foregoing.

07:22 EDT MeiraGTx announces data from the MGT009 Phase 1/2 clinical study - MeiraGTx (MGTX) announced top-line data from the Phase 1/2 clinical study MGT009 of botaretigene sparoparvovec, an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa, XLRP, with disease-causing variants in the RPGR gene. Treatment with botaretigene sparoparvovec was found to be generally safe and well-tolerated, and significant improvements were demonstrated in multiple endpoints across each of the three domains of vision - retinal function, visual function, and functional vision - in participants treated with botaretigene sparoparvovec when compared to the randomized untreated control arm of the study at 6 months post-treatment. MeiraGTx and Janssen Pharmaceuticals, one of the Janssen Pharmaceutical Companies of Johnson & Johnson (JNJ) are jointly developing botaretigene sparoparvovec as part of a broader collaboration to develop and commercialize gene therapies for the treatment of inherited retinal diseases. In the dose escalation and expansion phases of the MGT009 study, improvements in vision were seen in subjects treated with low and intermediate doses of botaretigene sparoparvovec compared to the randomized concurrent control arm at 6 months. Improvements were demonstrated in retinal sensitivity on static perimetry; functional vision in a vision-guided mobility assessment; and (other measures of visual function and functional vision. "We are extremely encouraged by these data which demonstrate improvement following treatment with botaretigene sparoparvovec compared to an untreated randomized control group in a range of endpoints that are relevant to this severe disease," said Alexandria Forbes, Ph.D., president and chief executive officer of MeiraGTx. "These data give us increased confidence in the potential for botaretigene sparoparvovec to meaningfully improve the lives of the thousands of patients with XLRP."

07:18 EDT Fate Therapeutics announces expansion of collaboration with ONO Pharmaceutical - Fate Therapeutics (FATE) announced that it has expanded its off-the-shelf, iPSC-derived, cell-based cancer immunotherapy collaboration with ONO Pharmaceutical (OPHLY) to include the development of chimeric antigen receptor, CAR, NK cell collaboration candidates. In addition, as part of the collaboration's expansion, ONO will contribute novel binding domains targeting a second solid tumor antigen. Under the original Collaboration and Option Agreement entered into between Fate and ONO in September 2018, ONO has contributed novel binding domains targeting an initial solid tumor antigen, and Fate is currently conducting preclinical development of a multiplexed-engineered, iPSC-derived CAR T-cell product candidate for solid tumors. "Our collaboration with ONO has focused on driving innovation in the field of cell therapy for solid tumors, and we are excited by the preclinical data we have observed with our first iPSC-derived CAR T-cell product candidate," said Scott Wolchko, President and Chief Executive Officer of Fate Therapeutics. "We are impressed with the differentiated antigen binders that ONO has contributed to the partnership, and we are pleased to expand our collaboration to initiate preclinical development of collaboration products targeting a second solid tumor antigen." Under the terms of the amended Collaboration and Option Agreement, Fate will advance iPSC-derived CAR NK and CAR T-cell product candidates to a pre-defined preclinical milestone, at which point ONO has an option to assume responsibility for worldwide development and commercialization with Fate retaining the right to jointly develop and commercialize in the United States and Europe. Fate retains all rights of manufacture of collaboration products on a global basis.

07:17 EDT React Gaming names Leigh Hughes as interim CEO - React Gaming Group announces the appointment of Leigh Hughes as its Interim Chief Executive Officer, effective immediately. Hughes replaces Laurent Benezra who is stepping down from his current role as President and CEO as well as director of the Corporation, but will remain in a consultancy role. Hughes is an entrepreneur and venture capitalist with over 20 years of experience working with private and public companies across the globe. He is also the founder of COMVERJ Ventures.

07:11 EDT Cendyn announces partnership with OpenTable - Cendyn is excited to announce its partnership with OpenTable to allow hotel and resort restaurants the ability to link key guest, dining and loyalty CRM data across both restaurant and hotel guest profiles. The new integration between Cendyn's eInsight CRM and OpenTable provides hotel-based restaurants visibility into holistic guest insights, bringing a unified view of profiles onto the OpenTable restaurant platform. This allows for personalized dining experiences and enables loyalty recognition across the entire guest journey at the restaurant and across the hotel property. Hotel guests can now be welcomed at a property's restaurant with personalized insights, including dietary and dining preferences, loyalty status, and other details related to their current or previous stays. This eliminates the complexity of managing two separate guest profiles and makes delivering incredible hospitality seamless and effortless for the hotel and dining teams. OpenTable is a part of Booking Holdings.

07:10 EDT Revolution Medicines doses first patient in Phase 1/1b trial of RMC-6236 - Revolution Medicines announced the first patient was dosed in its Phase 1/1b monotherapy clinical trial of RMC-6236, the company's oral, potent, tri-complex RAS(ON) Inhibitor designed to treat patients with cancers driven by a variety of RAS mutations. RMC-6236, which the company refers to as a RASMULTI (ON) Inhibitor, is the first development candidate from Revolution Medicines' portfolio of novel RAS(ON) Inhibitors to enter clinical development. The Phase 1/1b trial is a multicenter, open-label, dose-escalation and dose-expansion study of RMC-6236 in patients with advanced solid tumors harboring selected KRASG12 mutations, including KRASG12D, KRASG12V and KRASG12R. The primary objectives of the study are to evaluate safety and tolerability and to inform the recommended Phase 2 dose and schedule for the compound. "Beginning clinical evaluation of the first compound from our broad portfolio of RAS(ON) Inhibitors marks a significant milestone in our efforts to serve unmet needs of patients with RAS-addicted cancers," said Mark A. Goldsmith, M.D., Ph.D., chief executive officer and chairman of Revolution Medicines. "To our knowledge, RMC-6236 is the first oral, direct RAS inhibitor to be deployed against a tumor harboring the KRASG12D variant, and it ushers in a wave of groundbreaking RAS(ON) Inhibitors we expect to advance."

07:07 EDT Decibel reports data from interim analysis of Phase 1b trial of DB-020 - Decibel Therapeutics reported positive top-line results from an interim analysis of its ongoing Phase 1b clinical trial of DB-020, a novel, proprietary formulation of sodium thiosulfate, STS, designed to protect against hearing loss in cancer patients receiving cisplatin chemotherapy. Cisplatin, one of the most commonly used chemotherapeutic agents, has severe dose-limiting side effects, including ototoxicity, which leads to permanent hearing loss in many patients. There are no approved therapies to prevent or treat cisplatin-induced ototoxicity. Patients enrolled in the Phase 1b clinical trial were randomized to receive one of two doses of DB-020 in one ear while the contralateral ear received placebo, enabling each patient to serve as their own control. Consistent with the results of a Phase 1 clinical trial of DB-020 previously completed by the Company in healthy volunteers, data from the interim analysis demonstrated that DB-020 was well tolerated, with adverse events generally mild to moderate. Key findings: DB-020 was generally well tolerated, with no significant safety issues observed; DB-020, administered prior to cisplatin, had no apparent effect on systemic cisplatin levels; 13 of 17 patients experienced cisplatin-induced ototoxicity in the placebo ear after the first cycle of cisplatin; 15 of 17 patients experienced cisplatin-induced ototoxicity in the placebo ear by the last evaluable test; Placebo-treated ears lost approximately 30dB on average from baseline in high frequencies, shifting patients from normal or slight hearing loss to moderate hearing loss on average; In the 15 patients who experienced ototoxicity in the placebo ear by the last evaluable test, DB-020 protected 13 from ototoxicity in their DB-020-treated ear; 8 of 15 were completely protected, and 5 of 15 were partially protected; Ears treated with DB-020 lost approximately 8dB on average from baseline; DB-020 reduced cisplatin-induced loss of speech audibility by 80% as measured by the Speech Intelligibility Index, suggesting treatment with DB-020 may reduce the risk of needing assistive hearing devices after receiving cisplatin

07:06 EDT Digital Realty partners with HPE GreenLake - Digital Realty announced that it has launched Data Hub featuring HPE GreenLake Colocation on PlatformDIGITAL. The combination of these two solutions on Digital Realty's global platform creates an ideal meeting place for enterprises to bring their data together and consume infrastructure on demand, helping to unlock trapped value and drive innovation.

07:05 EDT Earthstone Energy to acquire New Mexico assets of Titus Oil & Gas for $627M - Earthstone Energy announced that it has entered into an agreement to acquire the New Mexico assets of Titus Oil & Gas Production and Titus Oil & Gas Production II and their affiliates located in the northern Delaware Basin. Titus is privately held with sponsorship by investment funds managed by NGP Energy Capital Management. The aggregate purchase price of the Titus Acquisition is approximately $627M consisting of $575M in cash and approximately 3.9M shares of Earthstone's Class A common stock valued at $52M based on a closing share price of $13.51 on June 24, 2022, both subject to customary closing adjustments. The effective date of the Titus Acquisition will be August 1 with closing anticipated in the Q3. The cash portion of the consideration is expected to be funded with cash on hand and borrowings under the Company's senior secured revolving credit facility. In conjunction with the Titus Acquisition, Earthstone has obtained $400M of incremental commitments from existing lenders, increasing elected commitments under the Credit Facility from the current $800M to $1.2B upon closing. Earthstone's current borrowing base is $1.4B and is expected to increase with the Titus Acquisition. June 2022 net production has averaged ~31,800 Boepd from 44 gross / 37 net operated wells and is inclusive of ~1,200 Boepd from non-operated interests. The board of directors of Earthstone has unanimously approved the Titus Acquisition. The board of directors and members of Titus Oil & Gas Production and Titus Oil & Gas Production II and those of their applicable affiliates have also unanimously approved the Titus Acquisition. Legal advisors included Haynes and Boone, and Jones & Keller, P.C. for Earthstone, and Bracewell, LLP for Titus. Jefferies acted as exclusive financial advisor to Titus.

07:04 EDT Exela Technologies announces contract with Cnam - Exela Technologies announced a contract with L'Assurance Maladie Caisse Nationale, Cnam, the French National Insurance Fund, utilizing Exela's PCH Global platform to speed up the National Agency's digital transformation. While the initial total contract value is $2.5M, the 4-year contract has the potential to grow to over $4.5M over this period. Initially, the solution will deploy Exela's cutting-edge Raptor and Intelliscan XDS scanners as well as a full OCR application across multiple sites as part of Exela ITPS segment. The online classification and extended sorting capacity will handle a wide range of document types and the initial deployment will be rolled out to two sites within 2022, with estimated volumes of 40,000 pieces per site per day, therefore optimizing social security and healthcare claims processing and management in France.

07:02 EDT Chemomab Therapeutics awarded new U.S. patent for CM-101 - Chemomab Therapeutics reported that the United States Patent and Trademark Office has issued a new patent for CM-101, Chemomab's first-in-class monoclonal antibody that neutralizes CCL24, a novel disease target at the confluence of fibrosis and inflammation. The new patent covers the use of CM-101 and sequence-related CCL24 antibodies for the treatment of hepatic diseases. CM-101 is currently in a Phase 2 trial for the treatment of primary sclerosing cholangitis, a potentially lethal disease affecting the bile ducts of the liver, as well as a Phase 2 liver fibrosis study.

06:57 EDT Evofem extending gains following Phexxi deal with PBM, up 25% in pre-market - Shares of Evofem are up 25% in pre-market trading following yesterday's advance of 187% after the company announced that it has reached an agreement with one of the nation's largest pharmacy benefit manager to ensure that most women covered by this plan can fill their Phexxi prescriptions for pregnancy prevention.

06:52 EDT Evofem reaches Phexxi agreement with PBM - Evofem announced it has reached an agreement with one of the nation's largest pharmacy benefit managers, or PBMs, to ensure most women covered by this plan can fill their Phexxi prescriptions for pregnancy prevention, without restrictions such as prior authorization or step therapy. With the removal of the prior authorization process for this PBM, starting on July 1, Evofem anticipates saving approximately $400,000 through the end of 2022 and close to $1M on an annualized basis.

06:49 EDT Frontier Group issues statement regarding proposed merger with Spirit - Frontier Group Holdings (ULCC), parent company of Frontier Airlines, issued the following statement regarding Frontier's proposed merger with Spirit (SAVE). "Over the last few weeks, JetBlue (JBLU) has proclaimed that Spirit management is hiding behind 'false' and "misleading" antitrust concerns so as to deny JetBlue the right to take over-and erase from existence-the nation's largest ultra-low cost carrier. JetBlue is not telling you the truth. A Spirit acquisition by JetBlue would lead to a dead end-a fact that no amount of money, bluster, or misdirection will change. And the only value Spirit stockholders would be likely to receive from JetBlue's proposal is the reverse termination fee, because JetBlue's proposal lacks any realistic likelihood of obtaining regulatory approval. JetBlue admitted that it will permanently remove capacity from the market by retrofitting Spirit's fleet to remove seats. Antitrust lawyers call that an 'output restriction,' and it is fatal to JetBlue's bid. So are JetBlue's admitted price increases. Less airline capacity means higher fares. JetBlue's CEO, Robin Hayes, certainly knows that. He observed just a few days ago, 'The average price of air fares will go up because there is [sic] less seats.' That is exactly what JetBlue would do with Spirit's fleet. Indeed, in announcing its bid on April 6, JetBlue said that the acquisition would increase its profit margins, despite higher costs. These facts-admitted higher prices and lower output-guarantee that JetBlue could never secure clearance for its proposed acquisition of Spirit. No claimed 'divestitures' of airport slots or gates, or false claims or gimmicks, can fix JetBlue's fatal problems. And these are not even JetBlue's only regulatory problems. The anticompetitive rationale for its bid is obvious. JetBlue even admitted it, stating in its 2021 10-K that the Frontier/Spirit deal is a threat to JetBlue's 'competitiveness'-and an example of a merger that 'could cause fares of our competitors to be reduced.' Mr. Hayes later conceded that 'the timing' of JetBlue's bid was 'definitely driven by the announcement' of the proposed ULCC merger. Then there is the U.S. Department of Justice's pending lawsuit against JetBlue to block its Northeast Alliance with American Airlines. Despite assuring everyone-including Spirit shareholders-that a transaction would spread the mythical, so-called 'JetBlue Effect,' Mr. Hayes previously admitted the DOJ's reason for bringing the NEA lawsuit: 'DOJ believes that American's influence will bring an end to the 'JetBlue Effect.' The DOJ has therefore already disputed JetBlue's arguments for a transaction. And, contrary to Mr. Hayes' assertion that the NEA litigation will be resolved shortly-and thus will have no effect either way on the JetBlue/Spirit acquisition-it will surely take years to resolve the NEA litigation, through trial and all inevitable appeals. While Spirit shareholders wait for what, exactly? A break-up fee, years later, out of the illusory JetBlue bid? For weeks, JetBlue has filled the airwaves with noise. It has shared an astonishing array of misleading claims, all while ignoring obvious and lethal antitrust problems. Indeed, just yesterday, JetBlue claimed that "outside experts agree that, within the current administration, our transaction has a similar chance as Frontier in gaining approval.' JetBlue includes no source, of course-so the 'outside experts' it appears to be talking about? Its very own, JetBlue-hired antitrust lawyer. JetBlue wants you to think that Frontier and JetBlue bring antitrust risk profiles that differ only in degree, not in kind. But nothing could be further from the truth. A JetBlue acquisition of Spirit could not succeed. A Frontier/Spirit merger is entirely different. Our transaction will increase output and reduce prices by bringing ultra-low fares to more routes in competition with larger, higher cost, higher fare airlines. A combined Frontier and Spirit will stimulate demand by inducing people to fly when the high fares offered by JetBlue and the Big Four would otherwise price them out of the market."

06:49 EDT Stanley Black & Decker to sell Stanley Oil & Gas business to Pipeline Technique - Stanley Black & Decker announced it has signed a definitive agreement for the sale of its Stanley Oil & Gas business to Pipeline Technique, a provider of solutions to the energy industry. The pending sale of Stanley Oil & Gas encompasses pipeline services and equipment businesses including CRC-Evans Pipeline International, Pipeline Induction Heat and Stanley Inspection, which generated combined revenues of approximately $140M in 2021. Stanley Black & Decker expects to incur a pre-tax, non-cash charge of approximately $125M to $200M related to the write-down of the Oil & Gas net assets, which will be excluded from adjusted earnings. The results of the Oil & Gas business will remain in continuing operations and will not be reclassified as discontinued operations. The transaction is subject to regulatory approval and other customary closing conditions.

06:32 EDT BiomX and Boehringer to collaborate to discover IBD microbiome biomarkers - BiomX announces a new collaboration with Boehringer Ingelheim to identify biomarkers for inflammatory bowel disease, or IBD. BiomX is a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria. Under the collaboration BiomX will utilize its XMarker microbiome-based biomarker discovery platform with the goal of identifying biomarkers for a pathogenic bacterium thought to be associated with IBD. Such biomarkers could help identify IBD patients that would benefit from potential therapies targeted at the microbiome. In September 2020, Boehringer Ingelheim and BiomX entered into their first collaboration, which focused on identifying biomarkers associated with patient phenotypes in IBD. The terms of the collaboration entitle BiomX to research payments and also include an option for Boehringer Ingelheim to negotiate an exclusive right to biomarkers discovered under the collaboration. BiomX retains the right to utilize the biomarkers as companion diagnostics for phage therapy.

06:19 EDT Sanofi reports Nexviadyme approved by EC for treatment of Pompe Disease - The European Commission has granted marketing authorization for Nexviadyme, an enzyme replacement therapy for the long-term treatment of both late-onset and infantile-onset Pompe disease, Sanofi announced. "Nexviadyme is the first and only newly approved medicine for Pompe disease in Europe since 2006, when the European Commission authorized the marketing of alglucosidase alfa, branded Myozyme," the company stated.

06:13 EDT Toshiba shareholders vote to add Elliott's Bhanji, Farallon's Imai to board - Toshiba shareholders have voted to approve the company's proposal to invite representatives from two foreign activist funds onto its board. The board will add Nabeel Bhanji, senior portfolio manager of Elliott Investment Management, and Eijiro Imai, managing director at Farallon Capital Japan, the company said.

06:07 EDT Ideaya Biosciences selects Pol Theta Helicase development candidate - Ideaya Biosciences (IDYA) announced selection of a potential first-in-class Pol Theta Helicase development candidate, or DC. The Pol Theta Helicase DC is a potential first-in-class small molecule inhibitor of the helicase domain of DNA Polymerase Theta. Ideaya is collaborating with GSK (GSK) on IND-enabling studies to support the evaluation of the Pol Theta Helicase DC in combination with niraparib, GSK's PARP inhibitor, for patients having tumors with BRCA or other homologous recombination mutations or homologous recombination deficiency. Ideaya and GSK are targeting an IND submission for the Pol Theta Helicase DC, subject to satisfactory completion of ongoing preclinical and IND-enabling studies, to enable first-in-human studies in the first half of 2023. Ideaya and GSK are collaborating on the ongoing IND-enabling studies, and GSK will lead clinical development for the Pol Theta program. GSK holds a global, exclusive license to develop and commercialize the Pol Theta Helicase DC and is responsible for all research and development costs for the program, including those incurred by Ideaya. Ideaya is eligible to receive future development and regulatory milestones of up to $485M aggregate, inclusive of preclinical and clinical milestones of up to $10M aggregate for advancing this asset through IND effectiveness. Upon potential commercialization, Ideaya will be eligible to receive up to $475M of commercial milestones and tiered royalties on global net sales by GSK, its affiliates and their sublicensees ranging from high single digit to sub-teen double digit percentages, subject to certain customary reductions.

06:04 EDT Clearway Energy signs binding agreement to acquire 413 MW wind portfolio - Clearway Energy, Inc. (NYSE: CWEN, CWEN.A) ("Company") today announced that it has entered into a binding agreement to acquire a portfolio of operating wind projects from Capistrano Wind Partners for, subject to closing adjustments, cash consideration of $255M, plus the assumption of approximately $160M of non-recourse debt. The Capistrano Portfolio consists of five utility-scale wind projects representing 413 MW of capacity located in Texas, Nebraska, and Wyoming that achieved commercial operations between 2008 to 2012. The assets within the portfolio sell power under power purchase agreements with investment-grade counterparties that have a weighted average remaining contract duration of approximately 10 years. The operations, maintenance and asset management of these projects have been and will continue to be provided by subsidiaries of the company's sponsor, Clearway Energy Group. The Capistrano Portfolio will also provide additional growth potential as the company will have the option to invest in future wind repowering opportunities that will be evaluated in partnership with Clearway Group. Concurrent with the acquisition of the Capistrano Portfolio, the company has also entered into a Development Agreement with Clearway Group, whereby Clearway Group will pay $10M to the company to partially fund the acquisition of the Capistrano Portfolio for an exclusive right to develop, construct, and repower the projects in the Capistrano Portfolio. After factoring in estimated closing adjustments, proceeds from the Rights Fee, and new non-recourse debt, the company expects its total long-term corporate capital commitment to acquire the Capistrano Portfolio to be approximately $110M-130M, which the company expects to fund with cash on hand. Based on current expected terms and conditions of the new non-recourse financing, the acquisition is expected to provide incremental annual levered asset CAFD on a five-year average basis of approximately $12M-14M beginning January 1, 2023. The company expects the transaction to close in the second half of 2022.

06:01 EDT Gilead's Kite announces EC approval of CAR T-cell therapy Yescarta - Kite, a Gilead company, announces that the European Commission has approved its CAR T-cell therapy Yescarta for the treatment of adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy. Yescarta has maintained orphan medicinal product designation in this indication.

05:42 EDT Enterprise Products subsidiary files tax abatements for six proposed projects - Enterprise Products Operating, a subsidiary of Enterprise Products, recently filed applications for tax abatements for six proposed projects, including a proposed ethane to ethylene cracker that could be located in one of at least three jurisdictions. The company said, "None of the six projects and their locations have been finalized, approved or sanctioned at this time. Furthermore, to clarify multiple media reports, while Enterprise has been working to develop and commercially underwrite an ethane to ethylene facility for a number of years, the company has neither approved nor sanctioned the construction of such a facility."

05:37 EDT WISeKey divests 51% controlling interest in arago GmbH to Ogara - WISeKey announced that it has transferred its 51% controlling interest in arago GmbH to Ogara. As previously announced on April 25, WISeKey signed a Share Purchase and Transfer Agreement to sell its 51% stake in arago to a German consortium of investors led by arago's founder through his investment company, Ogara. The transfer of the shares gives Ogara full control of arago's operations into the acquiring consortium, and establish the framework of the partnership between WISeKey and arago to work together on the increasing adoption of AI and IoT convergence as one of the primary factors driving the growth of the IoT market. The transfer does not affect WISeKey's right to the purchase price, the payment of which is expected in Q3. The transfer will, however, allow WISeKey to move ahead with its strategic vision of refocusing on the core business.

05:32 EDT Ericsson provides update on proposed acquisition of Vonage - Ericsson (ERIC) continues to work closely with the Committee on Foreign Investment in the United States as it reviews its proposed acquisition of Vonage (VG). The merger has cleared all other requisite foreign and U.S. regulatory approval requirements, and the parties are working to conclude the regulatory process as expeditiously as possible. Ericsson and Vonage remain committed to this transaction and are working towards closing before end of July.

05:28 EDT Kraft Heinz announces 12-year virtual power purchase agreement with Repsol - Kraft Heinz announced a 12-year virtual power purchase agreement, or vPPA, with Repsol, a multi-energy company operating across more than 20 countries and based in Madrid, Spain. This agreement is the company's first investment in wind energy and is designed to help Kraft Heinz achieve its aspiration of procuring the majority of its electricity from renewable sources by 2025. Kraft Heinz is expected to source over 90 gigawatt hours/year of renewable energy from Spanish producer Repsol's largest wind project, Delta II - equivalent to powering approximately 90% of Kraft Heinz's European manufacturing sites, which is the majority of its European load. The vPPA is expected to generate enough renewable electricity to power approximately 25,000 average EU households per year at its peak.

05:24 EDT MasterCard, Paysafe announce integration of Mastercard Send - Mastercard (MA) and Paysafe (PSFE) announced the integration of Mastercard Send into Paysafe's payments platform, enhancing the payout capabilities offered to Paysafe's merchant customers in the UK and EU. The addition of Mastercard Send is the latest extension of the ongoing relationship between the two companies which supports multiple Paysafe products and services. Mastercard Send enables people and organizations to send and receive money around the world in near real-time. It is designed to help banks, businesses and digital players modernize the way they send payments.

05:19 EDT TAL Education provides update on status under HFCAA - TAL Education updated its status under the Holding Foreign Companies Accountable Act, or HFCAA. The Company was provisionally named by the United States Securities and Exchange Commission as a Commission-Identified Issuer on June 24, following the Company's filing of the annual report on Form 20-F for the fiscal year ended February 28 with the SEC on June 14.The company said, "The Company understands that the SEC made such identification pursuant to the HFCAA and its implementation rules issued thereunder, and this indicates that the SEC determines that the Company used an auditor whose working paper cannot be inspected or investigated completely by the Public Company Accounting Oversight Board of the United States to issue the audit opinion for its financial statements for the fiscal year ended February 28, 2022. In accordance with the HFCAA, the SEC shall prohibit a company's shares or American depositary shares from being traded on a national stock exchange or in the over-the-counter trading market in the United States if the company has been identified by the SEC for three consecutive years due to PCAOB's inability to inspect the auditor's working paper. The Company has been actively monitoring market developments and evaluating all strategic options to protect the interest of its stakeholders. The Company will continue to comply with applicable laws and regulations in both China and the United States, and strive to maintain its listing status on the New York Stock Exchange."